Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 23:00 local time 11th of January 2021

Situation Report No. 215 - State of Kuwait 12th of January, 2021



	Glo	bal	Eastern Mediterranean Region		
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths	
Total	89,048,345	1,930,265	5,173,214	125,217	
New	660,993	11,061	24,082	381	

State of Kuwait

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	154,841	149,373	945	4,523	50	1,337,514
New	527	366	2	-	-	10,087

HIGHLIGHTS

- Arrivals coming to Kuwait have to present a coronavirus negative PCR with the validity period reduced to 72 hours instead of 96 starting from January 17.
- The Ministry of Education: No paper or online exams for the first semester of the current scholastic year (2020-2021).
- GCC member states are setting up a center to combat coronavirus and other epidemics.
- WHO produces evidence to recommendations: Methods used for assessing health equity and human rights considerations in COVID-19 and aviation, see link.
- Unicef publishes the "Vaccine Misinformation Management Field Guide", see link.
 WHO provides guidance on who can take the Pfizer-BioNTech COVID-19 vaccine, se
- WHO provides guidance on who can take the Pfizer-BioNTech COVID-19 vaccine, see link.

IMPORTANT LINKS

- MoH update of COVID-19: https://corona.e.gov.kw/en/
- WHO's COVID-19 weekly situation reports:

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

- $\bullet \ WHO's \ COVID-19 \ dashboard: \ https://covid19.who.int/$
- WHO Recommendations on methods used for assessing health equity and human rights considerations in COVID-19 and aviation:

https://www.who.int/publications/i/item/evidence-to-recommendations-methods-used-for-assessing-health-equity-and-human-rights-considerations-in-covid-19-and-aviation

• Unicef's Vaccine Misinformation Management Field Guide:

https://www.unicef.org/mena/reports/vaccine-misinformation-management-field-guide

• Who can take the Pfizer BioNTech COVID-19 vaccine: https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine



Who can take the Pfizer-BioNTech COVID-19 vaccine?

According to SAGE (WHO's Strategic Group of Experts on Immunization), the Pfizer-BioNTech COVID-19 mRNA vaccine is safe and effective. Nevertheless, there are specific populations for whom vaccination is not recommended for a variety of reasons. These populations currently include people with a history of severe allergies, (particularly it is contraindicated for People with a history of severe allergic reaction to any component of the vaccine), most pregnant women (except for those with unavoidable high risk of exposure such as health workers), international travellers who are not part of a prioritized group (due to limited supplies of the vaccine at present), and children under 16 (due to lack of data). Further studies are needed for immune-compromized persons. The priority is to start vaccinating health workers at high risk of exposure, followed by older adults, before immunizing the rest of the population. For more details see the link above.

IMPORTANT CONTACTS

• The National Focal Person is Dr Buthaina AlMudhaf, Assistant Undersecretary, Ministry of Health, email: AlMudhaf@gmail.com





